Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P51148
UPID:
RAB5C_HUMAN
Alternative names:
L1880; RAB5L
Alternative UPACC:
P51148; F8W1H5; Q6FH55; Q9P0Y5
Background:
Ras-related protein Rab-5C, known by its alternative names L1880 and RAB5L, plays a crucial role in protein transport, specifically in the regulation of vesicular traffic. This protein is a key component in the intricate process of intracellular transport, ensuring the precise delivery of vesicles to their designated locations within the cell.
Therapeutic significance:
Understanding the role of Ras-related protein Rab-5C could open doors to potential therapeutic strategies. Its pivotal function in vesicular traffic highlights its importance in cellular homeostasis and presents an opportunity for targeted drug discovery efforts.